<DOC>
	<DOCNO>NCT00679939</DOCNO>
	<brief_summary>The purpose study determine effect rosiglitazone bone postmenopausal woman type 2 diabetes mellitus</brief_summary>
	<brief_title>Study In Postmenopausal Women With Type 2 Diabetes Looking At Approved Diabetes Drugs And How They Affect Bone Health</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Female , &gt; 55 &lt; 80 year &gt; 5 year menopausal Type 2 Diabetes Mellitus ( T2DM ) diagnosis accord American Diabetes Association ( ADA ) , American Association Clinical Endocrinologists ( AACE ) , Canadian Diabetes Association ( CDA ) , World Health Organization/International Diabetes Federation ( WHO/IDF ) Drugna√Øve ( HbA1c &lt; = 9.0 % ) ; OR Prior monotherapy , submaximal dos metformin ( &lt; = 1000mg Metformin ) , sulfonylurea ( &lt; = 5mg Glyburide , &lt; = 10mg Glipizide &lt; = 8mg glimepiride ) full dose Januvia ( 100mg ) ( HbA1c &lt; = 8.5 % ) ; OR Prior monotherapy , &gt; submaximal dos metformin ( &gt; 1000mg ) sulfonylurea ( &gt; 5mg Glyburide , &gt; 10mg Glipizide &gt; 8mg glimepiride ) ( HbA1c &lt; = 7.0 % ) Weighs &lt; 300 lb ( 136.4 kg ) Two vertebra ( L1L4 ) suitable BMD measurement dual xray absorptiometry ( DXA ) Absolute BMD value consistent Tscore &gt; 2.5 femoral neck , lumbar spine total hip Type 1 Diabetes Mellitus ( T1DM ) history diabetic ketoacidosis ( DKA ) Renal hepatic disease ( clinically significant ) Hepatocellular reaction , severe edema , medically serious fluid event associate thiazolidinedione ( TZD ) Recent ( &lt; 6mos ) history clinical intervention angina myocardial infarction take nitrate Any stage heart failure , i.e . New York Heart Association ( NYHA ) class IIV Systolic BP &gt; 160mmHg diastolic BP &gt; 90mmHg antihypertensive Hypersensitivity TZDs , biguanides Prior treatment two oral antidiabetic ( OAD ) agents Bilateral hip replacement Concurrent disease affect bone metabolism Active malabsorption syndrome Serum calcium outside central lab reference range Thyroid replacement therapy , serum thyroid stimulate hormone ( TSH ) must within range Vitamin D deficiency Previous treatment : strontium , intravenous ( IV ) bisphosphonate , fluoride , hormone , calcineurin inhibitor methotrexate Chronic systemic corticosteroid [ e.g . glucocorticoid , mineralocorticoid ] treatment two intraarticular injection within past year use oral parenteral , longterm , highdose inhaled corticosteroid</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>bone</keyword>
	<keyword>x-ray absorptiometry</keyword>
	<keyword>bone biomarkers</keyword>
	<keyword>dual-energy</keyword>
	<keyword>bone mineral density</keyword>
</DOC>